Among several radioligands developed so far, [18F]Flortaucipir showed high sensitivity and specificity to AD-related NFTs [6, 7], and represents the first and, to date, the only tau PET tracer approved by the U.S.A. Food and Drug Administration to support the diagnosis in patients with suspected AD [8, 9]. Here, MAPT is linked to Alzheimer disease.